Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their impact in cancer remains largely unknown. Here, we extensively screened for p53 aggregation phenotypes in tumour biopsies, and identified nuclear inclusion bodies (nIBs) of transcriptionally inactive mutant or wild-type p53 as the most frequent aggregation-like phenotype across six different cancer types. p53-positive nIBs co-stained with nuclear aggregation markers, and shared molecular hallmarks of nIBs commonly found in neurodegenerative disorders. In cell culture, tumour-associated stress was a strong inducer of p53 aggregation and nIB formation. This was most prominent for mutant p53, but could also be observed in wild-type p53 cell lines, ...
The p53 isoform, Δ133p53β, is critical in promoting cancer. Here we report that Δ133p53β activity is...
The p53 isoform, Δ133p53β, is critical in promoting cancer. Here we report that Δ133p53β activity is...
Many p53 missense mutations possess dominant-negative activity and oncogenic gain of function. We re...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
The p53 tumor suppressor is one of the most frequently mutated genes in human cancers, up to 50% of ...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
The p53 isoform, Δ133p53β, is critical in promoting cancer. Here we report that Δ133p53β activity is...
The p53 isoform, Δ133p53β, is critical in promoting cancer. Here we report that Δ133p53β activity is...
Many p53 missense mutations possess dominant-negative activity and oncogenic gain of function. We re...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their imp...
The p53 tumor suppressor is one of the most frequently mutated genes in human cancers, up to 50% of ...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
p53, first described four decades ago, is now established as a master regulator of cellular stress r...
The p53 isoform, Δ133p53β, is critical in promoting cancer. Here we report that Δ133p53β activity is...
The p53 isoform, Δ133p53β, is critical in promoting cancer. Here we report that Δ133p53β activity is...
Many p53 missense mutations possess dominant-negative activity and oncogenic gain of function. We re...